Biomarker discovery further uncovers deeper biological signals to define meaningful subtypes, and accelerate the path to targeted treatments.
CODA subtyping studies investigate biological differences across patients to better understand who may respond to specific treatments.
Data/AI Multinomic Studies
CODA invests in multiomics studies and AI data analysis to have the data and tools to better understand which patients respond to which therapies: the backbone of precision medicine.
MELO Study
CODA partnered with ChronicleBio and Precision Life to launch the MELO Study, a study aimed to identify potential biomarkers that may help explain the biological underpinnings of Long COVID and ME/CFS.
These biomarkers have been associated with these syndromes in previous scientific studies. They can be used to identify factors that increase patient’s risk and narrow down potential causes of particular symptoms. These findings are not yet validated for diagnosis or treatment, but they provide a window into areas of biology that warrant deeper investigation.
Over time, these insights could enable the development of more targeted studies, improved diagnostics, new treatments, and a better understanding of why these conditions affect people so differently.
It was important to CODA that these results be returned as a meaningful give-back to patients, offering insight into how research models work and how their participation drives scientific progress.
